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Background
B cell hyperactivation, as well as loss of immunoregula-
tion of Epstein-Barr virus (EBV) infection, are believed
to contribute to AIDS-NHL. Elevated serum levels of
several cytokines and immune activation molecules are
seen prior to the diagnosis of AIDS-NHL [1]. In this
study, we quantified plasma levels of B cell activation-
associated molecules (sCD23, sCD27, sCD30, IgE), cyto-
kines (IL-6, IL-10, CXCL13), and AICDA expression,
prior to and after the initiation of treatment in persons
with AIDS-NHL in the AIDS Malignancies Consortium
(AMC) 034 study.
Material and methods
Plasma and PBMC were obtained from AIDS-NHL
patients (n=70) in the AMC 034 study, which evaluated
treatment of AIDS-NHL with EPOCH chemotherapy
and rituximab. Plasma was collected prior to the initia-
tion of therapy, and post-treatment, after the first cycle
of chemotherapy, and at 6 and 12 months following
completion of treatment. Biomarkers were quantified by
ELISA, AICDA expression by qPCR.
Results
Higher pre-treatment plasma levels of most of these B cell
activation-associated molecules (IL-6, IL-10, CXCL13,
sCD27, sCD30) were seen in AIDS-NHL patients, when
compared to HIV+ and HIV-negative reference groups.
However, sCD23 levels were lower post-AIDS-NHL than
typically seen in the years preceding NHL diagnosis. Addi-
tionally, AICDA expression in PBMC was not detected in
specimens collected after AIDS-NHL diagnosis. Treatment
of NHL was seen to result in decreased plasma levels of
these molecules, with decreased levels persisting for one
year following the completion of treatment. CXCL13 and
sCD27 decreased the most after treatment (mean levels
went from 487 pg/ml to 310 pg/ml, and 1,080 units/ml to
330 units/ml, respectively) and remained low at one year
following initiation of treatment (86.6 pg/ml and 362
units/ml, respectively). Pre-treatment levels of some of
these molecules (IL6, IL10, CXCL13) were associated with
subsequent response to lymphoma therapy, as were LDH
levels and IPI scores. Using a normalizing transformation
on CXCL13, CD27 and LDH, logistic regression analysis
showed that the only factor significantly correlated with
response was CXCL13.
Conclusions
Biomarkers for AIDS-NHL identified in prior epidemio-
logic studies were often further elevated post-AIDS-
NHL diagnosis, and decreased with treatment for NHL.
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ciated with a poorer subsequent response to treatment,
and was a better predictor of response than LDH levels
and IPI scores.
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